Under-reporting of Validation Efforts for Health Economic Models Persists Despite the Availability of Validation Tools: A Systematic Review

被引:0
作者
Abraham, Katharina [1 ]
Ramos, Isaac Corro [2 ]
Braal, C. Louwrens [3 ]
Feenstra, Talitha [4 ,5 ]
Kleijburg, Anne [6 ,7 ]
van Voorn, George A. K. [8 ]
Uyl-de Groot, Carin [9 ]
机构
[1] Erasmus Univ Rotterdam EUR, Erasmus Sch Hlth Policy & Management, Rotterdam, South Holland, Netherlands
[2] EUR, Inst Med Technol Assessment iMTA, Rotterdam, South Holland, Netherlands
[3] Erasmus Univ MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands
[4] Univ Groningen, Groningen Res Inst Pharm, Fac Sci & Engn, Groningen, Netherlands
[5] Natl Inst Publ Hlth & Environm RIVM, Bilthoven, Netherlands
[6] Maastricht Univ, CAPHRI Care & Publ Hlth Res Inst, Dept Hlth Serv Res, Maastricht, Netherlands
[7] Trimbos Inst, Netherlands Inst Mental Hlth & Addict, Ctr Econ Evaluat & Machine Learning, Utrecht, Netherlands
[8] Wageningen Univ & Res, Appl Math & Stat Biometr, Wageningen, Netherlands
[9] EUR, Erasmus Sch Hlth Policy & Management, Rotterdam, South Holland, Netherlands
关键词
EARLY BREAST-CANCER; COST-EFFECTIVENESS ANALYSIS; ADJUVANT TRASTUZUMAB; ENDOCRINE THERAPY; RECONSTRUCTION; HER2;
D O I
10.1007/s40273-025-01491-2
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objective In this study we aimed to identify possible changes over time in validation efforts and the way in which they are reported for model-based health economic (HE) evaluations, given the introduction of several new validation tools and methods in the past decade. Methods A systematic review was conducted using PubMed and Embase on published HE models for early breast cancer (EBC) for the period 2016 to 2024. AdViSHE-consisting of four validation categories that cover the main HE model aspects-was utilized to systematically evaluate the reported evaluation efforts. The percentage of studies reporting validation per category was compared with the review by de Boer et al. that covers the years 2008 to 2015. Results Of the 2199 records, 78 studies fulfilled the eligibility criteria. Reported validation efforts did not significantly improve compared with the previous period, except for the validation of input data by experts. Reporting on the validation of the conceptual model remained low with around 10% of the studies providing validation. Validation of the computerized model and validation against outcomes using alternative input data were the most underreported validation categories with < 4% of the studies. The validation of model outcomes, specifically cross validity and the comparison with empirical data, remained the most reported categories in this review also, with 52% and 36%, respectively. When validation efforts were reported, this was done in a non-systematic manner, and the tests and results were rarely detailed. Conclusion Overall reporting of validation efforts for model-based HE evaluations in the past decade did not significantly change compared with the previous decade.
引用
收藏
页数:10
相关论文
共 53 条
  • [11] Modeling Good Research Practices-Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1
    Caro, J. Jaime
    Briggs, Andrew H.
    Siebert, Uwe
    Kuntz, Karen M.
    [J]. VALUE IN HEALTH, 2012, 15 (06) : 796 - 803
  • [12] Simulation modeling of breast cancer endocrine therapy duration by patient and tumor characteristics
    Chandler, Young
    Schechter, Clyde
    Jayasekera, Jinani
    Isaacs, Claudine
    Kurian, Allison W.
    Cadham, Christopher
    Mandelblatt, Jeanne
    [J]. CANCER MEDICINE, 2022, 11 (02): : 297 - 307
  • [13] Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective
    Clarke, Caroline S.
    Hunter, Rachael M.
    Shemilt, Ian
    Serra-Sastre, Victoria
    [J]. PLOS ONE, 2017, 12 (03):
  • [14] Combining vascularized lymph node transfer with autologous breast reconstruction: A Surveillance, Epidemiology and End Results (SEER) Database cost-utility analysis
    Corkum, Joseph P.
    Bezuhly, Michael
    [J]. JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY, 2020, 73 (10) : 1879 - 1888
  • [15] Coyle D., 2024, Can J Health Technol, DOI [10.51731/cjht.2024.862, DOI 10.51731/CJHT.2024.862]
  • [16] Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2-, node-positive, high-risk early breast cancer in Italy
    Davie, Alison
    Traore, Sory
    Giovannitti, Massimo
    Pompilio, Giuseppe
    Lambton, Mark
    Cakar, Esra
    Chatterjee, Anuja
    [J]. GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2023, 10 : 62 - 69
  • [17] Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer
    de Boer, Pieter T.
    Frederix, Geert W. J.
    Feenstra, Talitha L.
    Vemer, Pepijn
    [J]. PHARMACOECONOMICS, 2016, 34 (09) : 833 - 845
  • [18] Cost-effectiveness Analysis Comparing Conventional, Hypofractionated, and Intraoperative Radiotherapy for Early-Stage Breast Cancer
    Deshmukh, Ashish A.
    Shirvani, Shervin M.
    Lal, Lincy
    Swint, J. Michael
    Cantor, Scott B.
    Smith, Benjamin D.
    Likhacheva, Anna
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (11):
  • [19] Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT
    Earl, Helena
    Hiller, Louise
    Vallier, Anne-Laure
    Loi, Shrushma
    McAdam, Karen
    Hughes-Davies, Luke
    Rea, Daniel
    Howe, Donna
    Raynes, Kerry
    Higgins, Helen B.
    Wilcox, Maggie
    Plummer, Chris
    Mahler-Araujo, Betania
    Provenzano, Elena
    Chhabra, Anita
    Gasson, Sophie
    Balmer, Claire
    Abraham, Jean E.
    Caldas, Carlos
    Hall, Peter
    Shinkins, Bethany
    McCabe, Christopher
    Hulme, Claire
    Miles, David
    Wardley, Andrew M.
    Cameron, David A.
    Dunn, Janet A.
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2020, 24 (40) : 1 - +
  • [20] Cost-effectiveness of six months versus 1-year adjuvant trastuzumab in HER2 positive early breast cancer in Egypt
    Elsisi, Gihan Hamdy
    Nada, Yousery
    Rashad, Noha
    Carapinha, Joao
    Noor, Ahmad O.
    Almasri, Diena M.
    Al Zaidy, Mostafa
    Foad, Ahmed
    Khaled, Hussien
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (06) : 575 - 580